Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Virology and Viral Diseases 2019

Virology & Viral Diseases 2019

Details of Virology & Viral Diseases 2019 Conference in Netherlands:

Conference Name Place Date

 Virology & Viral Diseases 2019

Amsterdam, Netherlands October 21-22, 2019

Conference Series LLC Ltd invites all the participants from all over the world to attend 14th International Conference Virology, Emerging Diseases & Vaccines during October 21-22, 2019 at Amsterdam, Netherlands which includes keynote presentations, Oral talks, Poster presentations and Exhibitions

For more details download our brochure here: https://virology.conferenceseries.com/conference-brochure.php

Virology & Viral Diseases 2019 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Virology, Emerging Viral Diseases and Vaccines. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Virology and Immunology.

All honourable authors are kindly encouraged to contribute to and help shape the conference through submissions of their research abstracts, papers and e-posters in all areas of Virology and Immunology are cordially invited for presentation at the conference.

Virology & Viral Diseases 2019 is anticipating participants from 40 and more countries across the globe and the two day conference will provoke plenary sessions, Keynote speeches, Poster, and Oral presentations. This program provides two days of robust discussions on recent advancements and new strategies for development of new materials for global requirements.

Get connected on Facebook, twitter, LinkedIn for latest update.

We would also like to bring to your kind notice that we have 300+ journals where you can publish your full length manuscripts at discounted price.If you are interested please contact 

[[email protected]protonmail.comfor further details.

Our pleasure to meet you in upcoming event…!!!

Why to attend ?

Why to attend?

Our Conference will provide a perfect platform addressing:

•          Laudable talks by the top-notch of the global scientific community

•          Sterling workshop sessions

•          Remarkable Awards and Global Recognition to meritorious Researchers

•          Global Networking with 50+ Countries

•          Novel Techniques to Benefit Your Research

For more information drop a mail on [email protected]

Sessions and Tracks

Track 01: General Virology

Virology is the scientific discipline concerned with the study of the biology of viruses and viral diseases, including the distribution, biochemistry, physiology, molecular biology, ecology, evolution and clinical aspects of viruses. Viruses also cause serious diseases in plants and livestock. Viruses have been implicated in a disease that is ravaging our honeybees, threatening natural pollination cycles and thus much of agriculture.  A major branch of virology is virus classification. Viruses can be classified according to the host cell they infect animal viruses, plant viruses, fungal viruses, and bacteriophages. Viruses cause many important infectious diseases, among them the common cold, influenza, rabies, measles, many forms of diarrhea, hepatitis, Dengue fever, yellow fever, polio, smallpox and AIDS. Herpes simplex causes cold sores and genital herpes and is under investigation as a possible factor in Alzheimer's. The study of the manner in which viruses cause disease is viral pathogenesis. The degree to which a virus causes disease is its virulence.

Track 02: Influenza and other Respiratory Virus Diseases

Influenza and acute respiratory virus disease is a field of public health of major international importance.  Recent epidemiological events - the 2009 pandemic of H1N1 influenza, first identified in Mexico; the occurrence of human cases of avian influenza A(H7N9) in China; the emergence of Middle East Respiratory Syndrome (MERS-CoV); and ongoing outbreaks of virulent avian influenza A(H5N1) in several countries; continue to highlight the requirement for international collaboration on respiratory virus research and development.  Acute respiratory infections (ARI) impose a significant burden of both morbidity and mortality on children worldwide. In 2000 alone, an estimated 1·9 million children under the age of five died as the result of ARI, accounting for 14% of total mortality in the age group. While most infections are fairly mild, self‐limiting, and confined to the upper respiratory tract, severe illnesses can also occur. Influenza infections can be life‐threatening, mainly among the elderly, yet present a risk for the entire human population in the wake of influenza pandemics. As a result of constant genetic mutations in the influenza virus, the effectiveness of vaccination depends on the continuous monitoring of circulating strains globally.

Track 03: Transmission of Viruses

Viral transmission is the process by which viruses spread between hosts. It includes spread to members of the same host species or spread to different species in the case of viruses that can cross species barriers. Transmissibility within human populations is a key determinant of epidemic potential. Many viruses that can infect humans are not capable of being transmitted by humans; most human transmissible viruses that emerge already have that capability at first human infection or acquire it relatively rapidly. Virus transmission to humans occurs via inhalation of aerosolized virus-contaminated rodent urine, saliva, and feces, rarely by rodent bites. Humans are usually considered as a dead-end host that does not transmit the virus further. For plant viruses, the pathways reviewed are vertical and horizontal transmission via pollen, and horizontal transmission by parasitic plants, natural root grafts, wind-mediated contact, chewing insects, and contaminated water or soil. For insect viruses, they are transmission by plants serving as passive “vectors,” arthropod vectors, and contamination of pollen and nectar.

Track 04: Viral Pathogenesis

Viral pathogenesis, then, is defined as “how viruses produce disease in the host.” The portrait of viral pathogenesis is the sum of functions through which a virus causes disease (virulence) and the host resists or is susceptible. To infect its host, a virus must first enter cells at a body surface. Common sites of entry include the mucosal linings of the respiratory, alimentary, and urogenital tracts, the outer surface of the eye. The term viremia describes the presence of infectious virus particles in the blood. These virions may be free in the blood or contained within infected cells. Virulence refers to the capacity of a virus to cause disease in an infected host. It is a quantitative statement of the degree or extent of pathogenesis. In general, a virulent virus causes significant disease, whereas an avirulent or attenuated virus causes no or reduced disease, respectively.

Track 05:Viral Genetics, Evolution and Dynamics

Viral genetics is the study of the mechanisms of heritable information in viruses, including genome structure, replication and genetic change. Viruses have been engineered as vectors for gene expression, vaccine development, and gene therapy. Viral genomes encode gene products that modulate host defenses, including the immune response, an elaborate system that evolved in large part to protect us against invading microorganisms like viruses. Ideally, pathogens are cleared by immune defenses with minimum damage to the host. However, in the process, the immune defenses themselves can also cause damage (immunopathology). Viral evolution refers to the heritable genetic changes that a virus accumulates during its life time, which can arise from adaptations in response to environmental changes or the immune response of the host. Because of their short generation times and large population sizes, viruses can evolve rapidly. RNA viruses have high mutation rates that allow especially fast evolution. An example is the evolution of drug resistance in HIV.  Viruses are believed to have played important roles in the evolution of cellular organisms. Though viruses aren’t technically living – they need a host organism in order to reproduce – they are subject to evolutionary pressures. The recent development of potent antiviral drugs not only has raised hopes for effective treatment of infections with HIV or the hepatitis B virus, but also has led to important quantitative insights into viral dynamics in vivo. Viral dynamics include virus population dynamics, the role of the immune system in limiting virus abundance, the dynamics of viral drug resistance.

Track 06: Structural and Molecular virology

Molecular virology refers to the study of viruses at the molecular level which involves the analysis of genes and gene products of viruses and study their interaction with host (human, plant or animal) cellular proteins. Structural Virology is the molecular mechanisum used by viruses to invade host cells establish an infection and ensure that progeny virus particles are released into the environment, all while evading the host's immune defenes.Viruses are the smallest self -replicationg organisms. Even though individually viruses are rather simple,as a group they are exceptionally diverse in both replication stratgies and structures. Many viruses are important human pathogens.

To study the life cycle of human virus, we use various technologies like X-ray crystallography, cryo-electron microscopy. We investigate macromolecular interactions associated with virus cell entry, genome replication, assembly, and maturation. Viruses are very simple enough that we can aspire to understand their biology at a molecular level. Our efforts are directed towards using structural information for the development of anti-viral drugs and vaccines.

Track 07: Transplant-Associated Viral Infections

Solid organ and hematopoietic stem cell transplant recipients are uniquely predisposed to develop clinical illness, often with increased severity, due to a variety of common and opportunistic viruses. Patients may acquire viral infections from the donor (donor-derived infections), from reactivation of endogenous latent virus, or from the community. Herpes viruses, most notably cytomegalovirus and Epstein Barr virus, are the most common among opportunistic viral pathogens that cause infection after solid organ and hematopoietic stem cell transplantation. The polyoma BK virus causes opportunistic clinical syndromes predominantly in kidney and allogeneic hematopoietic stem cell transplant recipients. Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significant side effects and are frequently ineffective.

Track 08: Veterinary virology

Viruses are smaller and simpler in construction than unicellular microorganisms, and they contain only one type of nucleic acid—either DNA or RNA—never both. As viruses have no ribosomes, mitochondria, or other organelles, they are completely dependent on their cellular hosts for energy production and protein synthesis. They replicate only within cells of the host that they infect. Animal virology developed largely from the need to control viral diseases in humans and their domesticated animals. Viruses, like other infectious agents, enter the animal body through one of its surfaces. They then spread either locally on one of the body surfaces or through lymphatic and blood vessels to produce systemic infection. Iridoviridae and African Swine Fever Virus, adenovirus, Papillomavirus and Polyomavirus, herpesvirus are some of the major viruses causing diseases in cattle. At least one major disease of each domestic animal species except sheep is caused by a herpesvirus, including such important diseases as infectious bovine rhinotracheitis, pseudorabies, and Marek's disease. However, there are several approaches to their prevention, control, and eradication. The most generally useful control measure is the use of vaccines.

Track 09: Viral Immunology and Immunopathology

Viral immunology is simply the study of immune responses to viruses. A prolonged tissue-damaging effect resulting from an immune reaction against viruses is considered immunopathology. Such situations most commonly involve persistent viruses, which are themselves often mildly cytodestructive in the absence of an immune reaction. Chronic tissue damage initiated by viruses can also result in development of an autoreactive and an occasionally oncogenic response.

Track 10: Clinical and Neuro Virology

Clinical Virology incorporates a spectrum of disciplines and information ranging from the X-ray crystallographic structure of viruses and viral proteins to the global socio-economic impact of disease. It encompasses events that include accounts ranging from epidemics impacting history to the identification of new agents and mechanisms of disease. Viruses are important pathogens of the nervous system.

Track 11: Viral Oncology

Viral oncology is a subdivision of oncology,in these it is concerned with treatment of  human cancers /tumors with virus particles. Viruses have long been used as tools to understand basic mechanisms of cancer development and progression. Many cellular proteins crucial in oncogenesis and tumor suppression were first discovered by studying tumor viruses. Approximately 20% of all cancers worldwide results from chronic infections, in specific, up to 15% of human cancers is characterized by a viral aetiology with higher incidence in Developing Countries. Certainly, the infectious nature of specific tumors has important implications in their prevention, diagnosis, and therapy. In the 21st Century, the research on viral oncology field continues to be dynamic, with new significant and original studies on viral oncogenesis and as a translational research from virology for the treatment of cancer. At present, only seven established human tumor viruses are known which include Epstein-Barr Virus (EBV), Human Papillomavirus (HPV), Hepatitis B and C viruses (HBV and HCV), Human T-cell lymphotropic virus-1 (HTLV-1), Human Herpesvirus-8 (HHV-8), and Merkel Cell Polyomavirus (MCPyV)., but numerous human cancers are suspected to have an infectious etiology that has not yet been identified. Discovery of each human tumor virus has spawned a new research field that has contributed to our understanding of infectious tumors and cancer biology.

Track 12: STD's and Non-Viral STIs

Sexually transmitted diseases (STDs), also known as sexually transmitted infections or STIs, are very common. STDs don’t always cause symptoms or may only cause mild symptoms, so it is possible to have an infection and not know it. If you are diagnosed with an STD, know that all can be treated with medicine and some can be cured entirely. Chlamydia, Gonorrhea, Hepatitis, Herpes, HIV/AIDS, Human Papillomavirus (HPV) Infection, Syphilis are some of the most common and most prevalent sexually transmitted diseases. Non-bacterial, non-viral organisms that can cause disease in humans include fungi, protozoa, helminths. The most important STD within this category will be discussed in this section, trichomoniasis. Nonviral infections are of special concern in young populations and have more serious consequences in women than in men. With perinatal exposure, newborns are at risk for both minor and major complications, including congenital anomalies, mental impairment, and death. If nonviral STIs are detected early, they can be treated, transmission to others can be eliminated, and sequelae can be averted. Appropriate emotional support and effective counseling are important components of infection management.

Track 13: Novel Antiviral Therapies

Antiviral therapy is one of the most exciting aspects of virology, since it has successfully employed basic science to generate very effective treatments for serious viral infections. Most drugs and vaccines, however, selectively target a single virus, thereby providing a “one drug-one bug” solution. In contrast, broad-spectrum antivirals (BSAs) can cover multiple viruses and genotypes and reduce the likelihood of development of resistance. Therefore, some BSAs can be used for the rapid management of new or drug-resistant viral strains, for a first-line treatment. There are two types of anti-viral therapies depending on the type of virus, they are: "episodic" oral antiviral therapy (where antiviral therapy is used intermittently by the patient during a recurrence), or "suppressive" antiviral therapy (where the antiviral therapy is taken continuously to prevent recurrences).

Track 14: New and Endogenous Retroviruses

Human endogenous retroviruses (HERVs) represent footprints of previous retroviral infection and have been termed “fossil viruses”. These viruses are spread through vertical transmission via the germline DNA. The role of HERVS in disease is not well understood. They may play a role in human cancers and autoimmune disease. While in baboons and mice there are ERVs that are transmissible as infectious viruses, this is not the case in humans. Human Endogenous Retroviruses (HERVs) may be triggers of autoimmune rheumatic disease. Most endogenous retroviruses are silent—the genes that they encode are not expressed or are expressed only under restricted conditions, although in some animals one or more endogenous retroviruses are normally expressed during the lifetime of an animal.

Track 15: Vaccines and the Microbiome

The bacteria that exist throughout the human body, known as the microbiome, play a variety of roles in the development of the immune system. This is particularly true during infancy when the microbiome and the immune response are developing in tandem. Most vaccines are administered in early childhood to prevent outbreaks of devastating childhood diseases. A higher relative abundance of the phylum Actinobacteria (oral and parenteral vaccines) and Firmicutes (oral vaccines) was associated with both higher humoral and higher cellular vaccine responses, while a higher relative abundance of the phylum Proteobacteria (oral and parenteral vaccines) and Bacteroidetes (oral vaccines) was associated with lower responses. Subjects whose intestinal microbiota is dominated by Bifidobacterium demonstrated a broader level of adaptive immune response to vaccinations. On the other hand, infants with higher ratios of Enterobacteriales, Pseudomonadales, and Clostridiales in their intestinal microbiota exhibited lower immune response to vaccination.

Track 16: Immunization and Immunotherapeutics

Immunization is the process whereby a person is made immune or resistant to an infectious disease, typically by the administration of a vaccine. Vaccines stimulate the body’s own immune system to protect the person against subsequent infection or disease. In addition to the initial immunization process, it has been found that the effectiveness of immunizations can be improved by periodic repeat injections or "boosters." Immunization is a proven tool for controlling and eliminating life-threatening infectious diseases and is estimated to avert between 2 and 3 million deaths each year. Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapeutic agents use or modify immune mechanisms. Use of these agents is rapidly evolving. A number of different classes of immunotherapeutic agents have been developed such as Monoclonal antibodies, Fusion proteins, Soluble cytokine receptors, Recombinant cytokines, Small-molecule mimetics, Cellular therapies.

Track 17: Vaccines against Emerging Diseases (Ebola/Zika/Dengue/Chik)

Track 18: Vaccines against tropical and neglected diseases

Neglected tropical diseases (NTDs) are a group of infectious diseases that are considered “neglected” because they have traditionally received relatively little attention from global governments and health organizations. More than 1.5 billion people suffer from one or more NTDs. The neglected tropical diseases (NTDs) represent a group of parasitic and related infectious diseases such as amebiasis, Chagas disease, cysticercosis, echinococcosis, hookworm, leishmaniasis, and schistosomiasis. A new generation of vaccines for the neglected tropical diseases (NTDs) have now advanced into clinical development, with the Na-GST-1/Alhydrogel Hookworm Vaccine already being tested in Phase 1 studies in healthy adults. Vaccine trials in Australia, New Zealand, Argentina, and China confirmed the efficacy of the EG95 recombinant antigen against E. granulosus infection in sheep and other host species. Independent vaccine trials carried out in pigs with the TSOL18 antigen in Mexico, Peru, Honduras, and Cameroon have all achieved 99–100% protection against an experimental challenge infection with T. solium. However there are challenges for further development and implementation of these vaccines.  

Track 19: Novel Vaccine Delivery Methods

Vaccines are recognized worldwide as one of the most important tools for combating infectious diseases. Despite the tremendous value conferred by currently available vaccines toward public health, the implementation of additional vaccine platforms is also of key importance.  In this regard, recent work has been focused on vaccine delivery systems, as an alternative to injectable vaccines, to increase antigen stability and improve overall immunogenicity. The Mucosal Delivery, Intradermal Vaccination, novel design strategies of nanomaterial carriers for vaccine delivery.

  • Advances in DNA Vaccines, TLRS and Combination Adjuvants
  • Latest techniques and advancements in Vaccine delivery systems
  • Nano patch Technologies
  • Needle-free vaccine delivery
  • Routes & Medical devices for vaccines delivery
  • Transdermal Delivery of Vaccines
  • Vehicle, Mineral Salt & Bacteria Derived Adjuvants

Track 20: Adult Vaccinations

Getting vaccinated is a lifelong, life-protecting job.  The need for vaccines does not go away with age. In fact, there are specific ages in your adult life when vaccinations are recommended. Also, protection from vaccines you received as a child can wear off over time, and there are more vaccines available now. Adult vaccines are determined by many factors including your age, lifestyle, health condition, and which vaccines you’ve received during your life. Getting vaccinated reduces the risk of getting diseases like shingles, measles, whooping cough and influenza, human papillomavirus (which can cause certain cancers), meningococcal disease, hepatitis A, hepatitis B, chickenpox, measles, mumps, and rubella. Vaccine side effects are usually mild (like soreness at the injection site) and go away on their own. Severe side effects are very rare. Flu vaccine is especially important for people with chronic health conditions, pregnant women, and older adults. Tdap vaccine to protect against Pertussis (whooping cough) and Td (tetanus, diphtheria) booster shot are also important vaccines for adults.

Track 21: Measles as re-emerging infectious disease

Measles was once an eradicated disease in parts of the world after vaccines were developed and administered in at-risk areas. It is caused by the measles virus (MeV) which is a single stranded RNA virus with genetic diversity based on the nucleoprotein gene, including 24 genotypes. Measles complications which include pneumonia, diarrhea, vomiting and encephalitis are more common among children under five years old and adults. Humans are the only natural hosts of measles virus. However, measles has made a comeback partly fuelled by a growing ‘anti-vax’ sentiment, in which people refuse to vaccinate their children due to false public information. Measles is the most infectious disease in the world, with the capability to spread quickly and in great distance. So far, the disease is in Europe, Asia and the Americas, and threatens to spread further. Cases of measles can be dangerous to both adults and children, and in some instances the disease is deadly. Death rates are one to two in every 1,000 cases, and children are most at risk. It can be prevented by MMR vaccine. The vaccine protects against three diseases: measles, mumps, and rubella. One dose of MMR vaccine is approximately 93% effective at preventing measles; two doses are approximately 97% effective. Almost everyone who does not respond to the measles component of the first dose of MMR vaccine at age 12 months or older will respond to the second dose.

Track 22: Epidemiology of Re-Emerging Infectious Diseases

Sometimes, an old disease reappears in a new clinical form that may often be severe or fatal. These are known as re-emerging diseases. A series of recent emerging infectious disease outbreaks, including the 2014 Ebola virus disease (EVD) epidemic in West Africa and the continuing Zika virus disease epidemic in the Americas, have underlined the need for better understanding of which kinds of pathogens are most likely to emerge and cause disease in human populations. Emerging infectious diseases caused by numerous micro-organisms have been affecting a region, country and sometimes the entire globe from time to time sporadically or in the form of small outbreaks to global pandemic like swine flu. Many diseases which were once considered to be no longer a threat to the public health have once again begun to re-emerge. Many new and emerging RNA and DNA viruses are zoonotic or have zoonotic origins in an animal reservoir that is usually mammalian and sometimes avian. Not all zoonotic viruses are transmissible (directly or by an arthropod vector) between human hosts. Some infectious diseases seem to be exacerbated by various factors, including rapid urbanization, large numbers of migrant workers, changes in climate, ecology, and policies, such as returning farmland to forests.

Track 23: Emerging infectious diseases and the "One Health" concept

“An emerging infectious disease (EID) is one that has appeared and affected a population for the first time, or has existed previously but is rapidly increasing, either in terms of the number of new cases within a population, or its spread to new geographical areas” One Health is defined as “a collaborative, multisectoral, and transdisciplinary approach—working at local, regional, national, and global levels—with the goal of achieving optimal health outcomes recognizing the interconnection between people, animals, plants and their shared environment. More than half of the known pathogens infectious to humans are shared with animals (“zoonotic” diseases), either via recurring transmission (e.g., rabies or plague) or from an initial spillover event (as is suspected with HIV/AIDS, which genetic analyses suggest probably originally emerged from great apes through contact during hunting or butchering). Public health topics with a One Health scope are as follows:

  • Environmental determinants of disease risk
  • Zoonotic and vector-borne disease risks
  • Antimicrobial resistance
  • Non-zoonotic diseases in animals
  • Noncommunicable diseases

Call for abstracts

Call for abstracts

Virology & Viral Diseases 2019 brings you an immense opportunity to be a part of scientific acceleration to world class personalities, young scholars, scientific delegates and young scientists to join in this Conference to utilize the expertise and novelties that brings a new era for innovations in the field of Virology & Immunology which brings well versed scrutinizers at one place. It provides a platform to have open discussions, knowledge sharing and interactive sessions with field experts at Virology 2019. We request you to submit a brief idea or abstract of your talk/presentation/symposium/workshop according to your session interest. Please follow the format of our Sample Template.

Abstract Submission Deadline: August 15, 2019

For abstract submisssion visit: https://virology.conferenceseries.com/abstract-submission.php

Market Analysis

Virology, the study of viruses, is an unparalleled branch of life sciences. With immensely high prevalence of diseases such as flu, hepatitis, AIDS, and STDs, the importance of virology is repeatedly highlighted. The global virology market is expected to grow over 2015-2025.

Global Virology Market
 
The global virology market is estimated at $1693 million in 2017 and is estimated to grow at a CAGR of 5.4% during the forecast period 2018-2023. North America is the largest virology market led by the U.S., owing to technological advancements such as rapid, portable diagnostics. N. America is expected to retain the top market position over the forecast period as well.
 
Europe is projected to maintain the position as the second largest market globally. During the forecast period, Europe is anticipated to record the highest CAGR, attributed by enhanced healthcare infrastructure, facilitated access to diagnostics, and growing affordability of diagnostic tests for viral diseases.
 
Japan is currently a growing virology market, which is estimated to grow at a remarkable CAGR through to 2025. However, APEJ and Africa are expected to witness the most promising growth opportunities during the forecast period. While China will be a leading APEJ market, India will contribute a considerable revenue share to the APEJ virology market.

 

Key Players in the Global Virology Market
 
The notable players identified in the global virology market include GlaxoSmithKline plc, Abbott Laboratories, Boehringer Ingelheim Corporation, Merck and Co. Inc., Novartis International AG, Siemens, Johnson & Johnson, AstraZeneca AB, and Roche.
 
Merck and Co. Inc. has several drug candidates in phase 2, including cancer, diabetes, cardiac arrest, and hepatitis C, and some candidates in phase 3, including breast cancer, atherosclerosis, Alzeimer's, ebola, and HIV. The company also has many other candidates, which are currently under review.
 
Abivax, a high profile biotech company in Paris, France, has already successfully produced candidates against dengue and chikungunya viruses. The company has a few more candidates against HIV and ebola, currently under development.
 
Virology Market: Segmentation
 
Virology Market is segmented By Product Type into Diagnosing Test: DNA Viruses, RNA Viruses, Prions Diagnostic Test, and Other Viral Tests.
 
On the basis of diagnosis tests, hepatitis B, Hepatitis C, HIV, Human papillomavirus (HPV), and other tests (like influenza, Ebola, and dengue) are estimated to hold the largest market share globally during the forecast period. Viral Infection controlling Methods include Immunoprophylaxis, Active Prophylaxis (Vaccines), Passive Prophylaxis, Antiviral Chemotherapy (Veridical Agents, Antiviral Agents, Immunomodulators), Interferon’s (Cytokines). Immunoprophylaxis therapy and antiviral drugs are the fastest growing market segments in the estimated forecast period.
 
Virology Market is segmented By Applications into Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Urinary Tract infection, Eye Infections, Sexually Transmitted Diseases, Perinatal Infections. STDs, Urinary tract infections, and respiratory tract infections are currently dominating as compared to the other application types in the global virology market. Virology Market is segmented By End Users into Hospitals, Clinics, Laboratories, Diagnostic Centers, Blood Banks, Pharmacies.
 

Global Vaccines Market: Snapshot

The global vaccine market is driven by the rise in prevalence of infectious diseases, as it is considered to be the best way to prevent such diseases. In addition, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), production of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs supplement the market growth.

According to the market research study in 2016, the global vaccines market was worth US$ 28.0 Bn and is projected to reach a value of US$ 48.0 Bn by the end of 2025. The market is predicted to register a promising 6.0% CAGR between 2017 and 2025.

 

Competitive Market Share

Some of the major players in global market are AstraZeneca, Abbott, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, Sanofi Pasteur, Pfizer, GlaxoSmithKline, Emergent BioSolutions, Novartis, Astellas Pharma, CSL and Novavax. Industry players focus on new product development, mergers, and acquisition to strengthen their market position. Companies should face intense competition for development of novel products.

 

VISA Information For Delegates

VISA Information For Delegates

It's the delegate's responsibility to investigate the visa requirements for Netherlands and to apply for a visa, if necessary. Individuals requiring an official Letter of Invitation from the conference organizers can request one by email by writing to us at [email protected]

To receive a Letter of Invitation, delegates, accompanying persons/children, student/post-doc/youth delegates and exhibitors must first register for the conference. The registration fee minus a handling fee of USD 100 will be refunded after the conference if the visa was applied for in time and proof is shown that a visa could not be granted even though all requested documents were submitted. Refund requests must be made in writing and sent to the Virology & Viral Diseases 2019 via email. All expenses incurred in relation to the conference are the sole responsibility of the delegate. The Letter of Invitation does not guarantee an entry visa to Netherlands. However, the conference organizers will not directly contact embassies   and consulates on behalf of delegates. The deadline for requesting a Letter of Invitation is two month before travelling to Netherlands.

Benefits for Delegates:

  • Meeting experts of their choice
  • Participation certification
  • Opportunity of obtaining special waiver if they are attending the conference in group from same organization
  • Networking and B2B meetings with the academic people attending the conference

For Delegates registration kindly visit: https://virology.conferenceseries.com/registration.php

Pre-Conference Workshop Invitation

Pre-Conference Workshop Invitation

The conference authority is planning to organize a preconference workshop with your support in your university/lab on a title related to Virology & Immunology or allied stream of your choice

The workshop can be scheduled as per your availability prior to main event. Workshop should be planned with 4-5 speakers and 40-50 attendees in the university or college premises.

All the required brochures & banners will be provided by us and will be sent to the venue of the preconference workshop before it's commencement.

The participants of this preconference workshop can be professors, associate professor, lecturer, instructor, counselors, or student of the same or different nearby universities.

In return we will provide certificate of participation to all the attendees signed by the organizer of the pre-conference workshop with prior confirmed list.

Virology & Viral Diseases 2019 in Amsterdam, Netherlands is the main event for which this preconference will be organized and to promote the attendance for the said main event.

Also all the workshop attendees will get an abatement of 25% on the registration for attending the conference of Virology & Viral Diseases 2019.

Hope this will have more benefits than expected and help us mutually to run the conference successfully. We would highly appreciate your opinion on the said proposal and await your positive response towards this.

Past Conference Report

Virology & Viral Diseases 2018

We gratefully thank all our wonderful speakers, conference attendees, students for making Virology & Viral Diseases 2018 Conference the best ever!

The 13th World Congress on Virology, Infections and Outbreaks hosted by the Conference Series LLC Ltd was held during December 05-06, 2018 at Vancouver, Canada based on the theme Advanced Research and Emerging Issues in the Field of Virology. Benevolent response was received from the Editorial Board Members of Conference Series LLC Ltd Journals along with scientists, researchers, students and leaders from various fields of Virology, who made this event a grand success. Conference Series will acknowledge with gratitude the support by all the Editorial Board Members of Journal of Virology and Pathology for their valuable suggestions for up growth of the Organization.

The conference was initiated with the Honorable presence of the Keynote forum. The list includes:

Joanna S Brooke, DePaul University, USA

Erin C Gaynor, The University of British Columbia, Canada

R.E.W. (Bob) Hancock, Centre for Microbial Diseases and Immunity Research, Canada

Erik Corona, Cigna, USA

Violet V Bumah, San Diego State University, USA

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

  • Respiratory Viral Infections
  • Viral Immunology
  • Antiviral Drugs
  • Herpes Simplex Virus
  • Clinical virology
  • Viral Oncology
  • Viral Vaccine
  • HIV, Diagnosis, Treatment and Current Research
  • Emerging Viral Diseases
  • Viral infection and their control
  • Epidemiology Of Viral Diseases
  • Deadliest Virus
  • Hepatitis B Virus Infection
  • Viral Diseases
  • Molecular virology
  • Food virology
  • Viral Gene Therapy
  • Neuro virology
  • Skin infection
  • Emerging Infectious Diseases
  • Diagnosis of Infectious Diseases
  • Infection Control
  • Gastrointestinal infections
  • Neonatal Infections
  • Gastrointestinal Infections
  • Urinary Tract Infection (UTI)
  • Diagnostic virology
  • Medical Virology
  • Plant Virology
  • Structural Virology
  • Viral Hepatitis
  • Veterinary Virology
  • Nipah virus (NiV)
  • Influenza virus

Conference Series LLC Ltd offers its heartfelt appreciation to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Conference Series LLC Ltd also took privilege to felicitate the Organizing Committee Members, Editorial Board Members and Media Partners who supported this event.

With the grand success of Virology & Viral Diseases 2018, Conference Series LLC Ltd is proud to announce the 14th International Conference on Virology, Emerging Diseases & Vaccines to be held during October 21-22, 2019 at Amsterdam, Netherlands. Virology & Viral Diseases 2018 has been prepared with the aim and the specific intent of promoting the development of new perspectives and ideas for exploiting the high level of knowledge achieved by the scientific community in Virology & Pathology disciplines.

For More details visit:  https://virology.conferenceseries.com/2018

To Collaborate Scientific Professionals around the World

Conference Date October 21-22, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

Journal of AIDS & Clinical Research Journal of Infectious Diseases & Therapy Virology & Antiviral Research

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by